In the current review article, we summarized the genetic alterations in non-AR proteins and discussed how targeting the same through PROTACs could be an effective strategy in the treatment of PC, as they may overcome resistance mechanisms that are associated with traditional targeted therapies. Here, AR is linked to pachyonychia congenita.